▲March 6-7Yangtze River Delta New Drug Innovators Summit
Scan for FreeRegistrationNote: This article does not constitute any investment opinions or recommendations.The information in this article is based on official/company announcements; this article only provides an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
Recently,Two Biotech Companies Go Public in IPOsMetsera and Maze Therapeutics have raised$275 millionAnd$140 million。It is reported that Metsera, a developer of obesity drugs, sold nearly 15.3 million shares at $18 per share, ranking among the largest offerings in the industry since 2022. Maze Therapeutics, a manufacturer of kidney disease drugs, issued more than 8.7 million shares at $16 per share.Metsera has been listed on NASDAQ with the stock code "MTSR," while Maze Therapeutics will be listed under the code "MAZE."
Metsera was founded in 2022.Dedicated to developing innovative therapies for obesity and metabolic diseases, develop a series of oral and injectable treatment options.Metsera Aims to Capture a Share of the Multi-Billion-Dollar Weight-Loss Drug Market by Improving Novo Nordisk's Semaglutide (Wegovy) and Eli Lilly's Tirzepatide (Zepbound). The company has raised over $500 million through two rounds of financing to acquire and test a series of oral and injectable drugs.In terms of financing, in April 2024, Metsera completed a $290 million Series A financing round led by ARCH Venture Partners, with participation from Google Ventures, F-Prime Capital, Softbank Vision Fund, and others. In November 2024, Metsera completed a $215 million Series B financing round led by Venrock Healthcare Capital Partners and Wellington Management, with participation from Fidelity, Google Ventures, and others.On January 7, Metsera announced its core productGLP-1 Drug MET-097iPositive Results from Phase 2a Clinical Trial. MET-097i may have a longer duration of action in the body compared to tirzepatide or semaglutide, under weekly dosing.Showed a weight loss effect of up to 11.3% after 12 weeks。Currently, the company is testing MET-097i as a once-weekly injection in other mid-stage trials for obesity and diabetes, and plans to evaluate its once-monthly dosing regimen in a third Phase 2 study, with data from two of the trials expected by 2025.
R&D Pipeline
Maze Therapeutics, founded in 2017, is a clinical-stage biopharmaceutical company focused on developing precision medicines.Translate Genetic Insights into Innovative Therapies, leveraging the power of human genetics to develop novel small-molecule precision medicines for patients with kidney, cardiovascular, and related metabolic diseases, including obesity. Its product pipelineMZE829It is an orally administered small molecule inhibitor developed for patients with APOL1 nephropathy. The Phase I clinical trial results published in October 2024 showed that the drug was well-tolerated, and the Phase II clinical trial was initiated in November 2024. The first patient dosing is expected to be completed in the first quarter of 2025, with proof-of-concept data anticipated in the first quarter of 2026.In terms of financing, in February 2019, Maze completed a $191 million Series A financing round led by ARCH Venture Partners and Third Rock Ventures; in January 2022, it received a $190 million investment led by Matrix Capital Management. Not long ago, it completed a $215 million Series D financing round.These funds have helped Maze Therapeutics develop drugs for kidney and metabolic diseases, as well as a treatment for Pompe disease, after which the company licensed out the rights to the Pompe drug. In November last year, a drug developed by Maze for a kidney disease caused by APOL1 gene mutations entered phase two testing, with data expected to be released in 2026. Maze stated that this drug has the potential to compete with a drug from Vertex Pharmaceuticals, which is currently in late-stage testing, as preclinical studies suggest that Maze’s drug may be "more potent" than Vertex's.In 2023, Maze Therapeutics granted its Pompe disease drug rights to Sanofi for the first time. However, after the Federal Trade Commission (FTC) raised a rare challenge to the deal, the rights were transferred to Shionogi the following year. According to Maze's IPO filing, the company also invested part of its research into two startups — Contour Therapeutics and Broadwing Bio.
R&D Pipeline
Over the past three years, about twenty biotech companies have gone public annually, but this number is far lower than the IPO boom during the COVID-19 pandemic. Experts predict that the number of biotech IPOs will increase in 2025. In January this year, in addition to Metsera and Maze Therapeutics going public, China's Ascentage Pharma successfully listed on the US NASDAQ on January 24, with the stock code "AAPG.NASDQ," becoming the first biopharmaceutical company to go public in the US in 2025 and the fourth innovative drug company to be listed in both Hong Kong and the US. Additionally, four more companies are in the queue for listing. These seven companies all have drugs in clinical trial stages, with four of them having reached at least phase two trials.Reference: Company Announcement
Copyright statement: This article is reproduced from Pharma Circle，Media or individuals who do not wish to be reprinted can contact us, and we will delete it immediately.
The conference recommendation is subject to the actual time and schedule.
